Taysha Gene Therapies

Taysha Gene Therapies, Inc.is a patient-centric, clinical-stage gene therapy company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for the treatment of monogenic diseases of the central nervous system. It also develops multiple gene therapy platforms which include AAV9 Discovery, Novel Capsid, and AAV Redosing. The company was founded by Steven Gray, Berge Minassian, and R. A. Session II in 2019 and is headquartered in Dallas, TX.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Taysha Gene Therapies advances TSHA-102 trials, secures financial stability

Taysha Gene Therapies showcased positive TSHA-102 trial results, faced financial challenges with increased expenses, and highlighted the potential of gene therapy in treating Rett syndrome. The company's focus on safety, sustained improvements, and regulatory advancements positions it for future success.

Taysha Gene Therapies reports positive TSHA-102 data and financial growth

Taysha Gene Therapies showcased promising advancements in the TSHA-102 program for Rett syndrome, supported by positive clinical data and a strengthened financial position.
While challenges exist in regulatory clarity and cost management, the company's strategic focus on data integrity and patient safety bodes well for future growth.
Opportunities for expansion, regulatory milestones, and market positioning through effective resource allocation and research advancements position Taysha for continued success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the fourth quarter and full-year ended December 31, 2021 and provided a corporate update. “2021 was a year of accomplishment that included positive data

Taysha Gene Therapies Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the initiation of clinical development of TSHA-102 for the treatment of Rett syndrome under a recently approved Clinical Trial Application (CTA) by Health Canada. Sainte-Jus

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-102 in Rett Syndrome

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the fourth quarter and full-year ended December 31, 2021, and host a corporate update conference call and webcast on Thursday,

Taysha Gene Therapies to Release Fourth Quarter and Full-Year 2021 Financial Results and Host Conference Call and Webcast on March 31

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in upcoming fireside chats at the Guggenheim Genomic Medicines and Rare Disease Day Conference and the 21st Annual Needham Virtual Healthcare Conference. C

Taysha Gene Therapies to Participate in Upcoming April Investor Healthcare Conferences

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in two fireside chats at the Oppenheimer 32nd Annual Virtual Healthcare Conference on Monday, March 14, 2022, and Tuesday, March 15, 2022. A webcast of bot

Taysha Gene Therapies to Participate in the Oppenheimer 32nd Annual Virtual Healthcare Conference

Shares of biopharmaceutical concern Taysha Gene Therapies, Inc. (TSHA) have lost over 70% of their value from their $20 IPO priced in September 2020.

Taysha Gene Therapies Gets A 'Thumbs Up'

Harrow Health Inc

Biotech insiders are among the most important investors to pay close attention to. Here are two that show good signs for the future.

Two Insider Moonshots Rising on Sudden Buying

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the presentation of clinical safety data supporting the first-generation construct at the highest dose of 1.0x1015 total vg for the treatment of CLN7 Batten disease at the 1

Taysha Gene Therapies Announces Positive Safety Data from UT Southwestern-Sponsored Clinical Trial for the Treatment of CLN7 Batten Disease at 18th Annual WORLDSymposium

Taysha Gene Therapies Inc TSHA has reported clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg and long-term durability data across all therapeutic doses of TSHA-120 in giant axonal neuropathy (GAN). [ALERT] Nic Chahine shares his Bear Market Beating options trading strategy.

Taysha Reports Efficacy, Safety Data From High Dose Cohort For Neurological Disorder Gene Therapy Trial

The stock price of Taysha Gene Therapies Inc (NASDAQ: TSHA) increased by over 18% pre-market today. This is why it happened.

Taysha Gene Therapies (TSHA) Stock: Why The Price Jumped Up Today

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported positive clinical efficacy and safety data for the high dose cohort of 3.5x1014 total vg, as well as long-term durability data across all therapeutic doses of TSHA-120 in gia

Taysha Gene Therapies Reports Positive Clinical Efficacy and Safety Data for High Dose Cohort and Long-term Durability Data for TSHA-120 in Giant Axonal Neuropathy

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported positive initial serum β-hexosaminidase A (Hex A) enzyme activity data for TSHA-101 in patients with Sandhoff and Tay-Sachs diseases, which represent two forms of GM2 ganglio

Taysha Gene Therapies Announces Positive Initial Biomarker Data For TSHA-101, the First Bicistronic Gene Therapy in Clinical Development, Demonstrating Normalization of β-Hexosaminidase A Enzyme Activity in Patients With GM2 Gangliosidosis

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that RA Session II, President, Founder and CEO of Taysha, will present a corporate overview at the 40th Annual J.P. Morgan Healthcare Conference on Thursday, January 13, 202

Taysha Gene Therapies to Present at the 40th Annual J.P. Morgan Healthcare Conference

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that RA Session II, President, Founder and CEO of Taysha, will participate in two panel discussions during the LifeSci Partners 11th Annual Corporate Access Event. Details f

Taysha Gene Therapies to Participate in Panel Discussions at the LifeSci Partners 11th Annual Corporate Access Event

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced plans to provide clinical data updates, including its intent to host two virtual investor conference calls and webcasts in January 2022 to discuss preliminary clinical data

Taysha Gene Therapies Announces January 2022 Virtual Investor Events to Review Preliminary Clinical Data for TSHA-101 in GM2 Gangliosidosis and High Dose Cohort and Long-Term Clinical Data for TSHA-120 in Giant Axonal Neuropathy

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has been added to the ICE Biotechnology Index (NYSE:ICEBIO) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on Mon

Taysha Gene Therapies Added to the ICE Biotechnology Index

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced preliminary clinical safety data for the first-generation construct in CLN7 disease. Preliminary clinical efficacy and safety data will be presented at the 18th Annual WORLD

Taysha Gene Therapies Announces Positive Preliminary Clinical Safety Data For First-Generation Construct In CLN7 Disease and Completion of Next-Generation CLN7 Construct Design

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced the initiation of clinical development of TSHA-118 for the treatment of CLN1 disease under a recently approved Clinical Trial Application (CTA). Queen's University in Ontari

Taysha Gene Therapies Announces Initiation of Clinical Development of TSHA-118 for the Treatment of CLN1 Disease

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it has been added to the Nasdaq Biotechnology Index (Nasdaq: NBI) in accordance with the annual reconstitution of the index, effective prior to the U.S. market open on

Taysha Gene Therapies Added to the Nasdaq Biotechnology Index

The stock price of Taysha Gene Therapies Inc (NASDAQ: TSHA) increased by over 7% during intraday trading today. This is why it happened.

Taysha Gene Therapies Stock (TSHA): Why The Price Increased Today

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced a late-breaking abstract and poster presentation by Dr. Rachel Bailey, Assistant Professor at UT Southwestern Medical Center on positive preclinical data for TSHA-105, an AA

Taysha Gene Therapies Announces Late-Breaking Abstract and Poster Presentation on Positive Preclinical Data For TSHA-105 Demonstrating Therapeutic Potential for the Treatment of Epilepsy Caused by SLCA13A5 Deficiency

Taysha Gene Therapies' (TSHA) CEO RA Session II on Q3 2021 Results - Earnings Call Transcript

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today reported financial results for the third quarter ended September 30, 2021 and provided a corporate update. “We made significant advances in multiple aspects of our business, including

Taysha Gene Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced its participation in the Stifel 2021 Virtual Healthcare Conference, Jefferies London Healthcare Conference, and the 4th Annual Evercore ISI HealthCONx Virtual Conference. Co

Taysha Gene Therapies to Participate in Upcoming November Investor Healthcare Conferences

DALLAS--(BUSINESS WIRE)--Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the third quarter ended September 30, 2021, and host a corporate update conference call and webcast on Wednesday, November 10,

News for Taysha Gene Therapies Stock (TSHA)